Roche, Senseonics extend diabetes monitor distribution deal to BRIC countries

For 2019, the company is projecting global revenues between $28 million and $32 million. (Senseonics)

Senseonics has extended and expanded its distribution agreement with Roche Diabetes Care for the next two years, giving the Big Biotech exclusive rights to sell its implantable glucose monitoring system in 17 additional countries, including Brazil, Russia, India and China.

Roche will also continue on as Senseonics’ exclusive distributor in Europe, the Middle East and Africa, outside of Scandinavia and Israel, while adding other markets in the Asia-Pacific and Latin American regions. The new agreement runs through January 2021.

“We are excited about the ongoing and incremental commitment from Roche, both from a geographic expansion and volume perspective,” said Senseonics President and CEO Tim Goodnow.


Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

“We believe that the positive reception that the Eversense CGM System has received in Europe is validation that patients and clinicians are experiencing the transformative power of a long-term CGM system,” Goodnow added.

RELATED: Senseonics debuts its 90-day Eversense CGM

Last year, Senseonics launched its 90-day Eversense system in the U.S. and its 180-day Eversense XL system in Europe. In a statement announcing its full year 2018 revenue results, Goodnow said that the U.S. launch is progressing along with the company’s expectations.

Unaudited preliminary revenue for 2018, according to Senseonics, was $19.7 million, compared to $6.4 million from the year before. For 2019, the company is projecting revenues between $28 million and $32 million.

RELATED: Roche helps Senseonics raise $41M to push diabetes device

About the size of a grain of rice, the Eversense sensor is implanted under the skin of the upper arm and uses a fluorescent glucose-indicating polymer to measure changes in blood sugar concentration, before relaying the data to an adhesive transmitter patch worn on the skin.

Roche had previously signed a distribution deal in 2016 with the Germantown, Maryland-based company, covering Germany, Italy and the Netherlands after the system received a CE mark.

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.